For millions of people with depression that won't respond to any medication, hope has just arrived in the most unexpected place. Psilocybin — the compound found in magic mushrooms — has now passed not one, but two Phase 3 clinical trials for treatment-resistant depression. The FDA submission is coming.
Compass Pathways announced that its proprietary synthetic psilocybin formulation, COMP360, successfully met the primary endpoint in its second Phase 3 trial (COMP006), following the same success in its first trial (COMP005). Both trials measured outcomes using the Montgomery-Åsberg Depression Rating Scale (MADRS) — the gold standard for depression research — and both delivered statistically significant reductions in depressive symptoms.
No classic psychedelic has ever done this before.
**What the Results Actually Mean**
In the COMP005 trial, 25% of participants who received the 25mg psilocybin dose achieved a clinically meaningful reduction in depression. In COMP006, that figure rose to 39% at the same dose. These might sound modest, but treatment-resistant depression is defined by its *resistance to everything else* — these are patients who have typically failed at least two antidepressants. A 39% meaningful response rate in this group is significant.
Perhaps more remarkable: data from COMP005 showed that the antidepressant effect was maintained for at least 26 weeks — over six months — from just one or two doses. That's not an everyday pill. That's a different kind of medicine entirely.
> *"COMP360 showed a rapid onset of antidepressant effects, often observed the day following administration."* > — Compass Pathways trial data
The safety profile was reassuring too. Most side effects — headache, nausea, transient visual effects — were mild-to-moderate and resolved within 24 hours. There was no clinically meaningful increase in suicidal ideation compared to placebo. For a population where that risk is always present, that matters enormously.
**FDA Breakthrough Designation**
The FDA had already granted COMP360 Breakthrough Therapy designation — a special status that accelerates development and review for drugs targeting serious conditions with unmet medical need. Compass Pathways plans to submit a New Drug Application (NDA) to the FDA by the end of 2026. If the agency moves on its usual timeline for breakthrough therapies, a potential approval could come in late 2026 or early 2027.
If approved, COMP360 would be the first classic psychedelic ever cleared for therapeutic use by the FDA.
**Who This Affects**
Treatment-resistant depression (TRD) affects an estimated 100 million people worldwide. In the UK alone, around 30% of people with depression don't respond adequately to standard antidepressants. These are people who have often tried multiple medications, each bringing side effects and disappointment. Many end up cycling through treatments for years. Some lose hope entirely.
Current options for TRD include electroconvulsive therapy (ECT), ketamine infusions, and transcranial magnetic stimulation. They work for some. They don't work for many. A single-dose or two-dose psychedelic therapy that produces six months of benefit would be genuinely transformative.
**A Wider Wave**
Compass Pathways isn't alone. Cybin's synthetic psilocybin compound is in Phase 3 trials for major depressive disorder, with results expected later in 2026. MindMed is conducting Phase 3 trials for an LSD-based therapy for depression. Australia has already moved ahead — psychiatrists there have been legally prescribing MDMA for PTSD and psilocybin for TRD since 2023.
Phase 3 — the large, rigorous, multi-site trials that regulators require for approval — was always the mountain to climb. Compass Pathways has now climbed it twice.
For everyone who has watched someone they love lose years of their life to depression that wouldn't yield — this matters. It's not a cure. It's not for everyone. But it's real, it's FDA-tracked, and it's coming. 💙
*Sources: Compass Pathways · Forbes · Psychiatric Times · BioWorld*
